Peregrine dives again as bavituximab data problems trigger loan call-in
This article was originally published in Scrip
Peregrine Pharmaceuticals' stock price fell 18.7% to $1.35 per share in after-hours trading on 26 September after the company revealed that it has enough cash to fund its operations only until early 2013, because major data discrepancies from a Phase IIb clinical trial for bavituximab in the treatment of non-small cell lung cancer (NSCLC) constituted a default and required repayment of a brand new $30 million loan.
You may also be interested in...
Merck’s third quarter beat analyst consensus and the company raised its guidance. The COVID-19-battered vaccines business began to improve but Gardasil’s recovery was slower than expected.
Amgen’s R&D programs are vitally important as sales of multiple blockbusters continue to drop, but one major late-stage asset had disappointing results and another key drug has an aggressive competitor.
The company has assembled small molecule discovery capabilities for the development of targeted cancer drugs that it believes rivals big pharma efforts and will fulfill patients’ unmet needs.